Nicole Germino
Stock Analyst at Truist Securities
(2.27)
# 980
Out of 5,370 analysts
30
Total ratings
66.67%
Success rate
30.19%
Average return
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
YMAB Y-mAbs Therapeutics | Maintains: Buy | 18 14 | 4.91 | 185.13% | 3 | May 14, 2025 | |
CATX Perspective Therapeu... | Maintains: Buy | 10 8 | 3.62 | 120.99% | 3 | May 14, 2025 | |
INSM Insmed | Maintains: Strong Buy | 105 108 | 101.26 | 6.66% | 8 | Feb 21, 2025 | |
SGMO Sangamo Therapeutics | Maintains: Buy | 7 5 | n/a | n/a | 5 | Jan 23, 2025 | |
FUSN Fusion Pharmaceutica... | Downgrades: Hold | 11 21 | n/a | n/a | 3 | Mar 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 13 13 | n/a | n/a | 3 | Oct 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 132 24 | 17.14 | 40.02% | 3 | Oct 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Sep 3, 2021 |